IL123453A - Pharmaceutical preparation for use in dementia - Google Patents

Pharmaceutical preparation for use in dementia

Info

Publication number
IL123453A
IL123453A IL12345398A IL12345398A IL123453A IL 123453 A IL123453 A IL 123453A IL 12345398 A IL12345398 A IL 12345398A IL 12345398 A IL12345398 A IL 12345398A IL 123453 A IL123453 A IL 123453A
Authority
IL
Israel
Prior art keywords
chain
composition
carbon atoms
branched
straight
Prior art date
Application number
IL12345398A
Other languages
English (en)
Hebrew (he)
Other versions
IL123453A0 (en
Inventor
Deutschland Gmbh Hmr
Original Assignee
Hmr Deutschland Gmbh Patent Un
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hmr Deutschland Gmbh Patent Un filed Critical Hmr Deutschland Gmbh Patent Un
Publication of IL123453A0 publication Critical patent/IL123453A0/xx
Publication of IL123453A publication Critical patent/IL123453A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
IL12345398A 1997-02-26 1998-02-25 Pharmaceutical preparation for use in dementia IL123453A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19707655A DE19707655A1 (de) 1997-02-26 1997-02-26 Kombinationspräparat zur Anwendung bei Demenz

Publications (2)

Publication Number Publication Date
IL123453A0 IL123453A0 (en) 1998-09-24
IL123453A true IL123453A (en) 2004-06-20

Family

ID=7821517

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12345398A IL123453A (en) 1997-02-26 1998-02-25 Pharmaceutical preparation for use in dementia

Country Status (30)

Country Link
US (1) US6037347A (id)
EP (1) EP0867192B1 (id)
JP (1) JP4374440B2 (id)
KR (1) KR100517186B1 (id)
CN (1) CN100363005C (id)
AR (1) AR011860A1 (id)
AT (1) ATE295738T1 (id)
AU (1) AU749278C (id)
BR (1) BR9800766A (id)
CA (1) CA2230350C (id)
CZ (1) CZ298367B6 (id)
DE (2) DE19707655A1 (id)
DK (1) DK0867192T3 (id)
EE (1) EE03387B1 (id)
ES (1) ES2242243T3 (id)
HR (1) HRP980097B1 (id)
HU (1) HUP9800396A3 (id)
ID (1) ID19941A (id)
IL (1) IL123453A (id)
MY (1) MY120530A (id)
NO (1) NO327200B1 (id)
NZ (1) NZ329839A (id)
PL (1) PL191576B1 (id)
PT (1) PT867192E (id)
RU (1) RU2194508C2 (id)
SI (1) SI0867192T1 (id)
SK (1) SK284925B6 (id)
TR (1) TR199800302A2 (id)
TW (1) TW590772B (id)
ZA (1) ZA981561B (id)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914251A (pt) * 1998-10-01 2001-06-19 Novartis Ag Formulações orais de liberação sustentada
US20040110776A1 (en) * 2002-02-22 2004-06-10 Iok-Hou Pang Use of propentofylline to control intraocular pressure
AU2003270446A1 (en) * 2002-09-25 2004-04-19 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
AU2005320547B2 (en) 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
AU2006241771B2 (en) * 2005-04-28 2010-09-09 Eisai R & D Management Co., Ltd. Composition containing anti-dementia drug
EP3347011A4 (en) 2015-09-11 2019-06-19 Chase Pharmaceuticals Corporation MUSCARIN COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGEN DISORDERS OF THE CENTRAL NERVOUS SYSTEM
RU2616247C1 (ru) * 2016-03-28 2017-04-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинский государственный университет имени Коста Левановича Хетагурова" (СОГУ) Твердая лекарственная форма, обладающая холинопозитивным действием, на основе 9-бутиламино-3,3-диметил-1,2,4-тригидроакридина

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737433A (en) * 1964-09-05 1973-06-05 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines
US3621096A (en) * 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
DE2330742C2 (de) * 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
JPH062675B2 (ja) * 1985-04-05 1994-01-12 ヘキストジヤパン株式会社 記憶障害治療剤
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
IL81610A (en) * 1986-02-27 1990-12-23 Roussel Uclaf Derivatives of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime,their preparation and pharmaceutical compositions containing them
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
IL87861A0 (en) * 1987-10-05 1989-03-31 Pfizer 4-aminopyridine derivatives
WO1989002739A1 (en) * 1987-10-05 1989-04-06 Pfizer Inc. 4-aminopyridine derivatives
DE3817955A1 (de) * 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
EP0491792A4 (en) * 1989-09-15 1992-12-02 Gensia Pharmaceuticals, Inc. Methods of treating neurodegenerative conditions
DE4236331A1 (de) * 1992-10-28 1994-05-05 Boehringer Ingelheim Kg Synergistische Kombination
US5783584A (en) * 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment

Also Published As

Publication number Publication date
PT867192E (pt) 2005-08-31
CA2230350A1 (en) 1998-08-26
RU2194508C2 (ru) 2002-12-20
HU9800396D0 (en) 1998-04-28
CN100363005C (zh) 2008-01-23
SI0867192T1 (en) 2005-10-31
JP4374440B2 (ja) 2009-12-02
KR100517186B1 (ko) 2005-12-05
PL325074A1 (en) 1998-08-31
TR199800302A3 (tr) 1998-09-21
BR9800766A (pt) 1999-12-07
DK0867192T3 (da) 2005-09-05
ID19941A (id) 1998-08-27
HUP9800396A1 (hu) 1999-07-28
HUP9800396A3 (en) 2001-05-28
US6037347A (en) 2000-03-14
DE19707655A1 (de) 1998-08-27
AU749278C (en) 2003-07-31
MY120530A (en) 2005-11-30
KR19980071717A (ko) 1998-10-26
HRP980097A2 (en) 1998-12-31
DE59812801D1 (de) 2005-06-23
CN1192904A (zh) 1998-09-16
AU5627398A (en) 1998-09-03
EE03387B1 (et) 2001-04-16
AR011860A1 (es) 2000-09-13
NO980786L (no) 1998-08-27
EP0867192A3 (de) 2000-12-06
ZA981561B (en) 1998-08-26
SK284925B6 (sk) 2006-02-02
JPH10236979A (ja) 1998-09-08
ATE295738T1 (de) 2005-06-15
EP0867192B1 (de) 2005-05-18
NZ329839A (en) 2000-05-26
CZ54098A3 (cs) 1998-09-16
TR199800302A2 (xx) 1998-09-21
CZ298367B6 (cs) 2007-09-12
SK24098A3 (en) 1998-09-09
HRP980097B1 (en) 2006-09-30
ES2242243T3 (es) 2005-11-01
NO327200B1 (no) 2009-05-11
EE9800075A (et) 1998-10-15
EP0867192A2 (de) 1998-09-30
AU749278B2 (en) 2002-06-20
TW590772B (en) 2004-06-11
IL123453A0 (en) 1998-09-24
PL191576B1 (pl) 2006-06-30
MX9801515A (es) 1998-08-30
NO980786D0 (no) 1998-02-25
CA2230350C (en) 2007-07-24

Similar Documents

Publication Publication Date Title
Schmid et al. A MAP kinase-signaling pathway mediates neurite outgrowth on L1 and requires Src-dependent endocytosis
Kawai et al. Nicotinic acetylcholine receptors containing α7 subunits on rat cortical neurons do not undergo long‐lasting inactivation even when up‐regulated by chronic nicotine exposure
Doerner et al. Cyclic GMP depresses hippocampal Ca2+ current through a mechanism independent of cGMP-dependent protein kinase
CA2230350C (en) Combination preparation for use in dementia
WO2014172616A2 (en) Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
EP1779867A1 (en) Nerve reveneration promoter
EP1666037A2 (en) Compositions for stimulating neurite growth
WO2010048273A2 (en) Methods and compounds for treatment of neurodegenerative disorders
HRP960372A2 (en) (1s, 2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate tridydrate
AU2012321345B2 (en) Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
TW201924676A (zh) Ｐ３８激酶抑制劑減少ｄｕｘ４及下游基因表現以供治療ｆｓｈｄ
AU2005309365B2 (en) Modulators of muscarinic receptors
US7132287B2 (en) Method for neural stem cell differentiation using 5HT-1A agonists
WO2013024164A1 (en) Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy
WO2012094615A2 (en) Use of cav3.1 selective t-type calcium channel antagonists
US20100129291A1 (en) Nicotinic desensitizers and methods of selecting, testing, and using them
Pruss et al. Cholera toxin stimulates division of 3T3 cells
Posern et al. Rapid lamellipodia formation in nerve growth factor‐stimulated PC12 cells is dependent on Rac and PI3K activity
Gagelin et al. Effects of cyclic AMP on components of the cell cycle machinery regulating DNA synthesis in cultured astrocytes.
MXPA98001515A (en) Prepared combination for application in the demen
Calderone et al. A farnesyltransferase inhibitor attenuates cardiac myocyte hypertrophy and gene expression
Lin et al. 2-Chloroadenosine decreases tyrosylprotein sulfotransferase activity in the Golgi apparatus in PC12 cells. Evidence for a novel receptor
AU6111996A (en) Methods and compositions for stimulating neurite growth
JP2002502355A (ja) ニューライトの成長を刺激するための方法および組成物

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees